hsa-miR-100

ncRNA information

ncRNA name

hsa-miR-100

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

No

Biomarker application

Upstream regulatory factors

Not available

Downstream target

mTOR/PLK1

Cancer information

Cancer name

Epithelial Ovarian Cancer

Cancer site

Ovary

Treatment information

Treatment type

Chemotherapy

Drug

Cisplatin

Impact of wild-type ncRNA on chemotherapy resistance

Down

Impact of knockdown of ncRNA on chemotherapy resistance

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.

Tissue resource

human ovary cancer cell lines SKOV3

human ovary cancer cisplatin-resistant cell lines SKOV/DDP

Experiment

qRT-PCR,Western blot


Institute

Cancer Research Institute of Southern Medical University

Qingdao University Medical College Affiliated Hospital

Country

China

Continent

Asia